BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 11029512)

  • 1. Opioid growth factor regulates the cell cycle of human neoplasias.
    Zagon IS; Roesener CD; Verderame MF; Ohlsson-Wilhelm BM; Levin RJ; McLaughlin PJ
    Int J Oncol; 2000 Nov; 17(5):1053-61. PubMed ID: 11029512
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Opioid growth factor (OGF) inhibits anchorage-independent growth in human cancer cells.
    Zagon IS; McLaughlin PJ
    Int J Oncol; 2004 Jun; 24(6):1443-8. PubMed ID: 15138586
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The opioid growth factor-opioid growth factor receptor axis: homeostatic regulator of cell proliferation and its implications for health and disease.
    McLaughlin PJ; Zagon IS
    Biochem Pharmacol; 2012 Sep; 84(6):746-55. PubMed ID: 22687282
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Opioid growth factor receptor is unaltered with the progression of human pancreatic and colon cancers.
    Zagon IS; McLaughlin PJ
    Int J Oncol; 2006 Aug; 29(2):489-94. PubMed ID: 16820893
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The opioid growth factor (OGF)-OGF receptor axis uses the p16 pathway to inhibit head and neck cancer.
    Cheng F; Zagon IS; Verderame MF; McLaughlin PJ
    Cancer Res; 2007 Nov; 67(21):10511-8. PubMed ID: 17974995
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overexpression of the opioid growth factor receptor potentiates growth inhibition in human pancreatic cancer cells.
    Zagon IS; Verderame MF; Hankins J; McLaughlin PJ
    Int J Oncol; 2007 Apr; 30(4):775-83. PubMed ID: 17332915
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Opioid growth factor-opioid growth factor receptor axis is a physiological determinant of cell proliferation in diverse human cancers.
    Zagon IS; Donahue RN; McLaughlin PJ
    Am J Physiol Regul Integr Comp Physiol; 2009 Oct; 297(4):R1154-61. PubMed ID: 19675283
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overexpression of the opioid growth factor receptor downregulates cell proliferation of human squamous carcinoma cells of the head and neck.
    McLaughlin PJ; Verderame MF; Hankins JL; Zagon IS
    Int J Mol Med; 2007 Mar; 19(3):421-8. PubMed ID: 17273790
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Growth inhibition of thyroid follicular cell-derived cancers by the opioid growth factor (OGF) - opioid growth factor receptor (OGFr) axis.
    McLaughlin PJ; Zagon IS; Park SS; Conway A; Donahue RN; Goldenberg D
    BMC Cancer; 2009 Oct; 9():369. PubMed ID: 19835629
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Opioid growth factor inhibits intimal hyperplasia in balloon-injured rat carotid artery.
    Zagon IS; Essis FM; Verderame MF; Healy DA; Atnip RG; McLaughlin PJ
    J Vasc Surg; 2003 Mar; 37(3):636-43. PubMed ID: 12618704
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reepithelialization of the human cornea is regulated by endogenous opioids.
    Zagon IS; Sassani JW; McLaughlin PJ
    Invest Ophthalmol Vis Sci; 2000 Jan; 41(1):73-81. PubMed ID: 10634604
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Opioid growth factor tonically inhibits human colon cancer cell proliferation in tissue culture.
    Zagon IS; Hytrek SD; McLaughlin PJ
    Am J Physiol; 1996 Sep; 271(3 Pt 2):R511-8. PubMed ID: 8853370
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting the opioid growth factor: opioid growth factor receptor axis for treatment of human ovarian cancer.
    Zagon IS; Donahue R; McLaughlin PJ
    Exp Biol Med (Maywood); 2013 May; 238(5):579-87. PubMed ID: 23856908
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interaction of opioid growth factor (OGF) and opioid antagonist and their significance in cancer therapy.
    Wang R; Zhang Y; Shan F
    Int Immunopharmacol; 2019 Oct; 75():105785. PubMed ID: 31404891
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulation of human head and neck squamous cell carcinoma growth in tissue culture by opioid growth factor.
    McLaughlin PJ; Levin RJ; Zagon IS
    Int J Oncol; 1999 May; 14(5):991-8. PubMed ID: 10200353
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The OGF-OGFr axis utilizes the p21 pathway to restrict progression of human pancreatic cancer.
    Cheng F; McLaughlin PJ; Verderame MF; Zagon IS
    Mol Cancer; 2008 Jan; 7():5. PubMed ID: 18190706
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cell proliferation of human ovarian cancer is regulated by the opioid growth factor-opioid growth factor receptor axis.
    Donahue RN; McLaughlin PJ; Zagon IS
    Am J Physiol Regul Integr Comp Physiol; 2009 Jun; 296(6):R1716-25. PubMed ID: 19297547
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutations in the opioid growth factor receptor in human cancers alter receptor function.
    Kren NP; Zagon IS; McLaughlin PJ
    Int J Mol Med; 2015 Jul; 36(1):289-93. PubMed ID: 26005722
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The opioid growth factor (OGF) and low dose naltrexone (LDN) suppress human ovarian cancer progression in mice.
    Donahue RN; McLaughlin PJ; Zagon IS
    Gynecol Oncol; 2011 Aug; 122(2):382-8. PubMed ID: 21531450
    [TBL] [Abstract][Full Text] [Related]  

  • 20. T lymphocyte proliferation is suppressed by the opioid growth factor ([Met(5)]-enkephalin)-opioid growth factor receptor axis: implication for the treatment of autoimmune diseases.
    Zagon IS; Donahue RN; Bonneau RH; McLaughlin PJ
    Immunobiology; 2011 May; 216(5):579-90. PubMed ID: 20965606
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.